Tourmaline Bio Gross Profit

Tourmaline Bio posts a gross profit of $20K as of June 2025. That compares with $-250K in the prior-year period — up 108.1% year over year. That is below the Healthcare sector average of $67B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Tourmaline Bio's gross profit was $-250K. The latest reading is $20K — a 108.1% year-over-year increase (period ending June 2025). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a gross profit near $67B is typical. Tourmaline Bio's $20K is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Gross Profit is one piece of Tourmaline Bio's financial statement story. At $20K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for TRML's gross profit usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $67B), and (3) consistency with growth and profitability. This page covers the first two; Tourmaline Bio's other metric pages and overview cover the third.